WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALNY

Based on 18 analysts offering 12 month price targets for Alnylam Pharmaceuticals Inc

Min Forecast
$330.00+5.71%
Avg Forecast
$459.94+47.34%
Max Forecast
$549.00+75.87%

Should I buy or sell ALNY stock?

Based on 18 analysts offering ratings for Alnylam Pharmaceuticals Inc.

Strong Buy
Strong Buy
11 analysts 61.11%
Buy
3 analysts 16.67%
Hold
4 analysts 22.22%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALNY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ALNY as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ALNY stock forecasts and price targets.

ALNY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-16
lockedlocked$00.00+00.00%2026-02-18
lockedlocked$00.00+00.00%2026-02-17
lockedlocked$00.00+00.00%2026-02-17Find Out Why
lockedlocked$00.00+00.00%2026-02-13
Needham
Top 1%
100
BuyMaintains$510.00+63.37%2026-02-12
Morgan Stanley
Top 8%
93
HoldMaintains$408.00+30.70%2026-01-30
Bank of America
Bottom 16%
16
Strong BuyMaintains$462.00+48.00%2026-01-30
Barclays
Top 16%
85
Strong BuyInitiates Coverage On$527.00+68.82%2026-01-28
RBC Capital
Top 13%
88
BuyMaintains$465.00+48.96%2026-01-20

1 of 2

Forecast return on equity

Is ALNY forecast to generate an efficient return?

Company
348.08%
Industry
67.77%
Market
181.01%
ALNY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALNY forecast to generate an efficient return on assets?

Company
55.31%
Industry
31.67%
ALNY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALNY earnings per share forecast

What is ALNY's earnings per share in the next 3 years based on estimates from 31 analysts?

Avg 1 year Forecast
$7.46+212.18%
Avg 2 year Forecast
$11.16+366.97%
Avg 3 year Forecast
$14.63+512.27%
ALNY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ALNY revenue forecast

What is ALNY's revenue in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$5.7B+53.5%
Avg 2 year Forecast
$7.5B+103.07%
Avg 3 year Forecast
$9.0B+142.17%
ALNY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ALNY earnings growth forecast

How is ALNY forecast to perform vs Biotechnology companies and vs the US market?

Company
83.15%
Industry
11.93%
Market
36.08%
ALNY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ALNY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ALNY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ALNY revenue growth forecast

How is ALNY forecast to perform vs Biotechnology companies and vs the US market?

Company
34.7%
Industry
35.63%
Market
13.33%
ALNY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ALNY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ALNY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALNY$312.17$459.94+47.34%Strong Buy
ARGX$663.93$1,038.20+56.37%Strong Buy
ONC$275.28$390.11+41.71%Strong Buy
INSM$136.00$214.63+57.81%Strong Buy
RPRX$45.36$47.75+5.27%Strong Buy
View Top Biotech Stocks

Alnylam Pharmaceuticals Stock Forecast FAQ

Is Alnylam Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 18 Wall Street analysts covering (NASDAQ: ALNY) stock is to Strong Buy ALNY stock.

Out of 18 analysts, 11 (61.11%) are recommending ALNY as a Strong Buy, 3 (16.67%) are recommending ALNY as a Buy, 4 (22.22%) are recommending ALNY as a Hold, 0 (0%) are recommending ALNY as a Sell, and 0 (0%) are recommending ALNY as a Strong Sell.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.

What is ALNY's earnings growth forecast for 2026-2028?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual earnings growth rate of 83.15% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and it is also forecast to beat the US market's average forecast earnings growth rate of 36.08%.

Alnylam Pharmaceuticals's earnings in 2026 is $313,747,000.On average, 31 Wall Street analysts forecast ALNY's earnings for 2026 to be $989,527,802, with the lowest ALNY earnings forecast at $635,556,631, and the highest ALNY earnings forecast at $1,428,749,130. On average, 28 Wall Street analysts forecast ALNY's earnings for 2027 to be $1,480,167,123, with the lowest ALNY earnings forecast at $1,007,272,779, and the highest ALNY earnings forecast at $2,087,421,975.

In 2028, ALNY is forecast to generate $1,940,714,253 in earnings, with the lowest earnings forecast at $1,406,282,770 and the highest earnings forecast at $2,505,184,879.

What is ALNY's revenue growth forecast for 2026-2028?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 34.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.33%.

Alnylam Pharmaceuticals's revenue in 2026 is $3,713,937,000.On average, 32 Wall Street analysts forecast ALNY's revenue for 2026 to be $756,084,543,944, with the lowest ALNY revenue forecast at $676,775,903,832, and the highest ALNY revenue forecast at $857,010,756,528. On average, 29 Wall Street analysts forecast ALNY's revenue for 2027 to be $1,000,243,752,048, with the lowest ALNY revenue forecast at $867,355,361,760, and the highest ALNY revenue forecast at $1,256,604,289,400.

In 2028, ALNY is forecast to generate $1,192,812,557,136 in revenue, with the lowest revenue forecast at $995,867,188,296 and the highest revenue forecast at $1,542,672,411,008.

What is ALNY's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ALNY) forecast ROA is 55.31%, which is higher than the forecast US Biotechnology industry average of 31.67%.

What is ALNY's Price Target?

According to 18 Wall Street analysts that have issued a 1 year ALNY price target, the average ALNY price target is $459.94, with the highest ALNY stock price forecast at $549.00 and the lowest ALNY stock price forecast at $330.00.

On average, Wall Street analysts predict that Alnylam Pharmaceuticals's share price could reach $459.94 by Mar 16, 2027. The average Alnylam Pharmaceuticals stock price prediction forecasts a potential upside of 47.34% from the current ALNY share price of $312.17.

What is ALNY's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ALNY) Alnylam Pharmaceuticals's current Earnings Per Share (EPS) is $2.39. On average, analysts forecast that ALNY's EPS will be $7.46 for 2026, with the lowest EPS forecast at $4.79, and the highest EPS forecast at $10.77. On average, analysts forecast that ALNY's EPS will be $11.16 for 2027, with the lowest EPS forecast at $7.60, and the highest EPS forecast at $15.74. In 2028, ALNY's EPS is forecast to hit $14.63 (min: $10.60, max: $18.89).

What is ALNY's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ALNY) forecast ROE is 348.08%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.